logo-loader
AIM:SLN

Silence Therapeutics PLC

Receive alerts
Market:
AIM
Market Cap:
£372.72 m
Price
450.00 GBX
Change
5.14%
52 weeks high
646.50
52 weeks low
82.50

In brief

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

Deep dive We explore the investor case for growth companies

Snapshot

  • AstraZeneca deal is worth up to US$1.4bn
  • Deals also with Mallinckrodt and Takeda
  • Heart drug to file for IND this year